← All trials
NCT06561867
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 30, 2024
- Primary completion
- Nov 30, 2025
- Completion date
- Dec 20, 2025
- First posted
- Aug 20, 2024
- Last posted
- Aug 20, 2024
- Enrollment
- 900
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kafrelsheikh UniversityLead sponsor
- Kafrelsheikh UniversityOfficial
- Kafrelsheikh UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.